CN102743410A - Use of Acaudina leucoprocta polysaccharide in pharmacy - Google Patents
Use of Acaudina leucoprocta polysaccharide in pharmacy Download PDFInfo
- Publication number
- CN102743410A CN102743410A CN2012102145097A CN201210214509A CN102743410A CN 102743410 A CN102743410 A CN 102743410A CN 2012102145097 A CN2012102145097 A CN 2012102145097A CN 201210214509 A CN201210214509 A CN 201210214509A CN 102743410 A CN102743410 A CN 102743410A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- fragrant
- septicemia
- east sea
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a use of an Acaudina leucoprocta polysaccharide in pharmacy and especially discloses a use of the Acaudina leucoprocta polysaccharide in preparation of a drug for treating septicemia. The Acaudina leucoprocta polysaccharide can improve a survival rate of a mice suffering from septicemia, reduce the number of pathogenic bacteria in a mice suffering from septicemia and reduce pro-infammatory cytokines in a mice suffering from septicemia.
Description
Technical field
The present invention relates to Stichopus japonicus polysaccharide and in pharmacy, use, be specifically related to the fragrant gracilis polysaccharide in the East Sea and in pharmacy, use.
Background technology
Stichopus japonicus polysaccharide has different physiological roles such as the tumor of inhibition, anticoagulation, neuroprotective tissue.Like publication number is CN1446543, and name is called the application for a patent for invention of Stichopus japonicus polysaccharide preparation, just discloses the preparation that utilizes Stichopus japonicus polysaccharide and vitamin E or mannitol to form, and can have enhancing immunity, and cancer-resisting suppresses effects such as tumor.The fragrant ginseng in the East Sea (
Acaudina leucoprocta, cry beche-de-mer in East China Sea or white anus Stichopus japonicus again) in Zhejiang, Fujian and Guangdong Coastal resources on continental shelf are very abundant, have produced the Stichopus japonicus industry of an annual value of production more than 100 hundred million.
Summary of the invention
Technical problem to be solved by this invention provides the fragrant gracilis polysaccharide in a kind of East Sea and in pharmacy, uses, and the fragrant gracilis polysaccharide in the East Sea has the survival rate that improves trouble septicemia mice, reduces the effect of suffering from septicemia mice pathogenic bacterium number.
The present invention solves the problems of the technologies described above the technical scheme that is adopted: the fragrant gracilis polysaccharide in the East Sea is used in pharmacy, specifically is the application of the fragrant gracilis polysaccharide in the East Sea in preparation treatment septicemia medicine.
The fragrant gracilis polysaccharide in the East Sea can be formed various preparations with pharmaceutically acceptable carrier, like oral liquid, tablet, ball, capsule etc., mice dosage with 50-200 μ g/g body weight every day, once a day, is irritated stomach with physiological water dissolving back.
The fragrant gracilis polysaccharide method for distilling in the East Sea is with reference to Zhang; H. wait people's document " Structural characterization and anti-inflammatory activity of two water-soluble polysaccharides from Bellamya purificata " (Carbohydrate Polymers 81 volumes; 4 phases; 960 pages of 953 –, 2010).
Compared with prior art; The invention has the advantages that the fragrant gracilis polysaccharide in the East Sea uses in pharmacy; Specifically be the application of the fragrant gracilis polysaccharide in the East Sea in preparation treatment septicemia medicine; Can improve the survival rate of suffering from the septicemia mice, reduce the effect of suffering from septicemia mice pathogenic bacterium number, reduce septicemia mice pro-inflammatory cytokine.
The specific embodiment
Below in conjunction with embodiment the present invention is described in further detail.
Embodiment 1
The septicemia mouse model is set up: 300 mices are divided into fragrant gracilis polysaccharide group in the East Sea and matched group at random, and every group each 150, the fragrant gracilis polysaccharide group in the East Sea was with East Sea perfume gracilis polysaccharide continuous irrigation stomach 30 days; Once a day, it is 100 μ g/g that the fragrant gracilis polysaccharide in the East Sea is irritated stomach dosage, and the fragrant gracilis polysaccharide in the East Sea is dissolved in 200 μ l normal saline and irritates stomach again; Matched group was irritated stomach 30 days with 200 μ l continuous normal saline, irritated stomach and finished the pentobarbital sodium anesthesia of mice with 80 mg/kg is cut the abdominal cavity and taken out caecum; Under ileocecal valve, use the cotton thread ligation, the caecum of ligation part adopts No. 22 pinpricks twice, and caecum is put back to the abdominal cavity; Sew up the abdominal cavity, obtain the septicemia mouse model.
Embodiment 2
Septicemia mouse model to the foregoing description 2 foundation; Get each 50 of fragrant gracilis polysaccharide group in the East Sea and matched groups, observe survival and the record of a mice every day, continue 8 days; Matched group septicemia mouse model is dead entirely after 8 days; 18 survivals of the fragrant gracilis polysaccharide group septicemia mouse model in the East Sea explain that the fragrant gracilis polysaccharide in the East Sea can improve the survival rate of suffering from the septicemia mice, and survival rate reaches 35%.
Embodiment 3
To the septicemia mouse model that the foregoing description 2 is set up, get each 50 of fragrant gracilis polysaccharide group in the East Sea and matched groups, observe the mice that sacrifice lives after 3 days; Get the mice whole blood and win Mouse Liver and the spleen tissue; Respectively to after each tissue homogenate of liver, spleen and blood, spread plate, 37 ° of C cultivate 18 h; Calculate the clump count of each sample; The mice clump count of the fragrant gracilis polysaccharide group in East Sea septicemia mouse model as a result: 19600/milligram tissues of hepatic tissue clump count average out to, spleen are organized 53200/milligram tissues of clump count average out to, 187000/milligram tissues of haemal tissue clump count average out to; The mice clump count of matched group septicemia mouse model: 42100/milligram tissues of hepatic tissue clump count average out to, spleen are organized 82700/milligram tissues of clump count average out to, 683000/milligram tissues of haemal tissue clump count average out to; Explain that the fragrant gracilis polysaccharide in the East Sea can reduce the pathogenic bacterium number of septicemia mice.
Embodiment 4
To the septicemia mouse model that the foregoing description 2 is set up, get fragrant gracilis polysaccharide group in the East Sea and respectively 50 of matched groups, get the mice whole blood that lives after observing 24 h; In blood, add anticoagulant; Centrifugal 15 min of 3500 rpm get blood plasma, adopt Enzyme Linked Immunoadsorbent Assay to detect short inflammatory factor interleukin-11 β and tumor necrosis factor; The expression of anti-inflammatory factor interleukin-11 0; As a result in the mice plasma of the fragrant gracilis polysaccharide group in East Sea septicemia mouse model: interleukin-11 β average out to 680pg/ml, tumor necrosis factor average out to 590pg/ml, interleukin-11 0 average out to 940pg/ml; In the mice plasma of matched group septicemia mouse model: interleukin-11 β average out to 1100pg/ml, tumor necrosis factor average out to 1260pg/ml, interleukin-11 0 average out to 990pg/ml; Explain that the fragrant gracilis polysaccharide in the East Sea can obviously reduce short inflammatory factor interleukin-11 β and the expression of tumor necrosis factor in blood plasma in the septicemia mice, and do not influence the expression of anti-inflammatory factor interleukin-11 0.
The toxicology of the fragrant gracilis polysaccharide in embodiment 5 East Sea detects
The fragrant gracilis polysaccharide in the East Sea that adopts 1 mg/g and two kinds of dosage of 10 mg/g is continuously to mouse stomach 30 days, and the 1 mg/g dosage mice of irritating stomach does not demonstrate tangible toxicity sign as a result, and death does not take place the mice that 10 mg/g dosage are irritated stomach.
Claims (1)
1. the fragrant gracilis polysaccharide in the East Sea is used in pharmacy, it is characterized in that the application of the fragrant gracilis polysaccharide in the East Sea in preparation treatment septicemia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102145097A CN102743410A (en) | 2012-06-27 | 2012-06-27 | Use of Acaudina leucoprocta polysaccharide in pharmacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102145097A CN102743410A (en) | 2012-06-27 | 2012-06-27 | Use of Acaudina leucoprocta polysaccharide in pharmacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102743410A true CN102743410A (en) | 2012-10-24 |
Family
ID=47024140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102145097A Pending CN102743410A (en) | 2012-06-27 | 2012-06-27 | Use of Acaudina leucoprocta polysaccharide in pharmacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102743410A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103463191A (en) * | 2013-08-20 | 2013-12-25 | 李颖 | Oral medicament for bacterial sepsis and preparation process thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101248890A (en) * | 2008-04-03 | 2008-08-27 | 侯书胜 | Nutrition reinforced type high activity beche-de-mer products and method of preparing the same |
| CN101343332A (en) * | 2008-08-20 | 2009-01-14 | 山东省科学院生物研究所 | Method for extracting holothurian polyoses with holothurian processing waste liquor |
| CN102040667A (en) * | 2010-10-30 | 2011-05-04 | 中国海洋大学 | Method for biologically removing protein from sea cucumber polysaccharide |
-
2012
- 2012-06-27 CN CN2012102145097A patent/CN102743410A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101248890A (en) * | 2008-04-03 | 2008-08-27 | 侯书胜 | Nutrition reinforced type high activity beche-de-mer products and method of preparing the same |
| CN101343332A (en) * | 2008-08-20 | 2009-01-14 | 山东省科学院生物研究所 | Method for extracting holothurian polyoses with holothurian processing waste liquor |
| CN102040667A (en) * | 2010-10-30 | 2011-05-04 | 中国海洋大学 | Method for biologically removing protein from sea cucumber polysaccharide |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103463191A (en) * | 2013-08-20 | 2013-12-25 | 李颖 | Oral medicament for bacterial sepsis and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102440986B (en) | Application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression caused by radiation or chemicals | |
| CN101953985A (en) | Drug with function of removing heat from lung to relieve cough | |
| Kim et al. | Do Escherichia coli extract and cranberry exert preventive effects on chronic bacterial prostatitis? Pilot study using an animal model | |
| CN102284041A (en) | Preparation technology and production method of integrated novel Pingwei powder dosage form | |
| CN102743410A (en) | Use of Acaudina leucoprocta polysaccharide in pharmacy | |
| CN102283928A (en) | Technology for preparing novel integrated dosage form of Ermiao powder and production method thereof | |
| CN103638055B (en) | Polyhachis vicina Roger extract and and antifungal pharmaceutical purposes thereof | |
| CN103638052A (en) | Polyrhachis dives extractive, and preparation and medical purpose thereof | |
| CN104116821B (en) | A kind of medical composition and its use of anti-inflammatory and antalgic | |
| CN103110734B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN113318149A (en) | Jasminum extract and preparation method and application thereof | |
| CN102283943A (en) | Preparation technology of integrated novel Simiao Yongan decoction dosage form | |
| CN103860578A (en) | Use of lentinan as antidepressant drug | |
| CN101757016A (en) | Medicine composition for treating flu and preparation method thereof | |
| CN101375857B (en) | Application of yew polysaccharide in preparing medicament for myocardial ischemia-reperfusion injury | |
| CN111000919A (en) | Application of ethanol extract of evodia lepta in preparation of medicine for treating sepsis | |
| CN105919991B (en) | Application of the euparin in preparation medicament for treatment of depression | |
| CN102283948A (en) | Preparation technology and production method of integrated novel Wuwei Xiaodu drink dosage form | |
| CN102512391B (en) | Azelnidipine quick-releasing drug preparation and preparation method | |
| CN104382927B (en) | Application of basil polysaccharide as taxol synergist in preparing antineoplastic drugs | |
| CN102284045A (en) | Banxia Houpo Tang integrated novel dosage form preparation technology and production method thereof | |
| CN102283922A (en) | Technology for preparing novel integrated dosage form of hemoptysis prescription and production method thereof | |
| CN105560238B (en) | A kind of pharmaceutical composition and its preparation method and application containing ginkolide B and phosphodiesterase inhibitors | |
| CN104997818A (en) | Application of total saponins of helleborus thibetanus franch in preparing drugs for preventing and treating liver injuries | |
| CN104188954A (en) | Medicine capable of stabilizing vascular plaques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121024 |